Commonwealth Equity Services LLC Sells 29,350 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Commonwealth Equity Services LLC cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 63.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,600 shares of the biopharmaceutical company's stock after selling 29,350 shares during the period. Commonwealth Equity Services LLC's holdings in Dynavax Technologies were worth $212,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Nordea Investment Management AB raised its position in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock worth $10,034,000 after purchasing an additional 232,690 shares during the last quarter. Barclays PLC boosted its holdings in Dynavax Technologies by 137.4% in the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after acquiring an additional 175,118 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Dynavax Technologies in the fourth quarter worth about $990,000. Wellington Management Group LLP acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth approximately $758,000. Finally, Bank of New York Mellon Corp boosted its stake in Dynavax Technologies by 4.4% in the fourth quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company's stock valued at $11,893,000 after acquiring an additional 39,513 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DVAX. The Goldman Sachs Group lowered shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their price objective for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. HC Wainwright restated a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th.

Dynavax Technologies Stock Down 0.0 %

Shares of DVAX traded down $0.00 during midday trading on Tuesday, hitting $11.44. The stock had a trading volume of 221,500 shares, compared to its average volume of 2,203,484. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 63.34 and a beta of 1.26. The company has a 50 day simple moving average of $13.17 and a two-hundred day simple moving average of $12.59. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to analysts' expectations of $72.70 million. On average, analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.